PLoS Pathogens (Aug 2022)

Universal protection against influenza viruses by multi-subtype neuraminidase and M2 ectodomain virus-like particle.

  • Ki-Hye Kim,
  • Zhuo Li,
  • Noopur Bhatnagar,
  • Jeeva Subbiah,
  • Bo Ryoung Park,
  • Chong Hyun Shin,
  • Peter Pushko,
  • Bao-Zhong Wang,
  • Sang-Moo Kang

DOI
https://doi.org/10.1371/journal.ppat.1010755
Journal volume & issue
Vol. 18, no. 8
p. e1010755

Abstract

Read online

Annual influenza vaccination is recommended to update the variable hemagglutinin antigens. Here, we first designed a virus-like particle (VLP) displaying consensus multi-neuraminidase (NA) subtypes (cN1, cN2, B cNA) and M2 ectodomain (M2e) tandem repeat (m-cNA-M2e VLP). Vaccination of mice with m-cNA-M2e VLP induced broad NA inhibition (NAI), and M2e antibodies as well as interferon-gamma secreting T cell responses. Mice vaccinated with m-cNA-M2e VLP were protected against influenza A (H1N1, H5N1, H3N2, H9N2, H7N9) and influenza B (Yamagata and Victoria lineage) viruses containing substantial antigenic variations. Protective immune contributors include cellular and humoral immunity as well as antibody-dependent cellular cytotoxicity. Furthermore, comparable cross protection by m-cNA-M2e VLP vaccination was induced in aged mice. This study supports a novel strategy of developing a universal vaccine against influenza A and B viruses potentially in both young and aged populations by inducing multi-NA subtype and M2e immunity with a single VLP entity.